Æ÷½ºÅÍ : ºÎÀÎÁ¾¾çÇÐ |
- ÀϽà : 2015³â 9¿ù 18ÀÏ(±Ý) ~ 2015³â 9¿ù 19ÀÏ(Åä)
- Àå¼Ò : EXHIBITION HALL B[1F] |
(07:00~07:00) |
|
89-GO107:00~07:00 |
°ÁöÀº ¿¬¼¼´ëÇб³ ¿øÁÖ¼¼ºê¶õ½º±âµ¶º´¿ø »êºÎÀΰú |
Basaloid Squamous Cell Carcinoma of the Uterine Cervix: A Case Report |
90-GO207:00~07:00 |
°íÁ¤È °¿ø´ëÇб³º´¿ø »êºÎÀΰú |
5¼¼ ¿©¾Æ¿¡¼ ¹ß»ýÇÑ °ñ¹Ý³» Á¾±«¿¡ ´ëÇÑ º¹°°æÀû ¼ö¼ú ¼º°ø 1¿¹ |
91-GO307:00~07:00 |
°øÁø°æ ¿¬¼¼ÀÇ´ë °³²¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
Primary ovarian mucinous carcinoid with metastatic adenocarcinoma in the contralateral ovary |
92-GO407:00~07:00 |
°øÅÂ¿í ¾ÆÁÖ´ëÇб³º´¿ø »êºÎÀΰú |
Pure large neuroendocrine carcinoma of the endometrium: A case report |
93-GO507:00~07:00 |
°øÅÂ¿í ¾ÆÁÖ´ëÇб³º´¿ø »êºÎÀΰú |
A predictive model for parametrial invasion in patients with FIGO stage IB cervical cancer: individualized
approach for primary treatment |
94-GO607:00~07:00 |
°øÅÂ¿í ¾ÆÁÖ´ëÇб³º´¿ø »êºÎÀΰú |
Ultrasound-guided intranodal lymphangiography with glue embolization: A novel technique to treat chylous
or lymphatic ascites after retroperitoneal lymphadenectomy in gynecologic cancer |
95-GO707:00~07:00 |
È«ÁøÈ °í·ÁÀÇ´ë ±¸·Îº´¿ø »êºÎÀΰú |
CXCL11 mediates Twist-induced angiogenesis in epithelial ovarian cancer cell line |
96-GO807:00~07:00 |
±Çº´¼ö ¼¿ï´ëÇб³ ºÐ´çº´¿ø »êºÎÀΰú |
Clinical determination of the appropriate time of removal of surgical drain in patients undergoing lymphadenectomy for the treatment of gynecologic cancer |
97-GO907:00~07:00 |
±Çº¸¶÷ Â÷ÀÇ°úÇдëÇб³ ºÐ´çÂ÷º´¿ø »êºÎÀΰú |
Choriocarcinoma Presenting Isolated Adrenal Metastasis: A case report |
98-GO1007:00~07:00 |
±âÀº¿µ °¡Å縯ÀÇ´ë ¼¿ï¼º¸ðº´¿ø »êºÎÀΰú |
Incidence and risk factors of lower extremity lymphedema after gynecologic surgery in ovarian cancer |
99-GO1107:00~07:00 |
±èµ¿¿í ÀÎÁ¦ÀÇ´ë ÇØ¿î´ë¹éº´¿ø »êºÎÀΰú |
The characteristics of Type II endometrial cancer. |
100-GO1207:00~07:00 |
±è¹Î°æ À»ÁöÀÇ´ë À»Áöº´¿ø »êºÎÀΰú |
Krukenberg tumor in pregnancy mimicking preeclampsia. |
101-GO1307:00~07:00 |
±è¼±¾Æ
|
The impact of 10 most common HPV genotypes on the progression of cervical cytology in women with ASCUS or LSIL: The Korean HPV cohort study |
102-GO1407:00~07:00 |
±è¼ÒÀ±
|
Incidental Serous Tubal Intraepithelial Carcinoma and Invasive Serous Carcinoma related with
BRCA mutation |
103-GO1507:00~07:00 |
±èÀ±È ºÎ»ê´ëÇб³º´¿ø »êºÎÀΰú |
Subserosal leiomyosarcoma of the uterus mimicking ovarian carcinoma in a postmenopausal woman : a case report
|
104-GO1607:00~07:00 |
±èÁöÇý Ä¥°î°æºÏ´ëÇб³º´¿ø »êºÎÀΰú |
Solitary retroperitoneal pelvic metastasis mimicking ovarian fibroma from hepatocellular carcinoma: a case report |
105-GO1707:00~07:00 |
±èÅÂÇö °Ç¾ç´ëÇб³º´¿ø »êºÎÀΰú |
HPV TYPE ATTRIBUTION AT DIFFERENT STAGES OF CERVICAL LESIONS PROVEN BY
CONIZATION BIOPSY : A SINGLE CENTER |
106-GO1807:00~07:00 |
±èÅÂÈÆ ¿øÀÚ·ÂÀÇÇпø »êºÎÀΰú |
Pelvic Reirradiation as an effective alternative to pelvic exenteration in recurrent cervical cancer |
107-GO1907:00~07:00 |
±èÅÂÈñ ¼øõÇâÀÇ´ë ºÎõº´¿ø »êºÎÀΰú |
Vagina Leiomyosarcoma : a Case Peport |
108-GO2007:00~07:00 |
±èÈ¿Áø ÀüÁÖ¿¹¼öº´¿ø »êºÎÀΰú |
Vaginal melanoma with uterine prolapse |
109-GO2107:00~07:00 |
±èÈñ½Â ¼¿ï´ëÇб³º´¿ø »êºÎÀΰú |
Laparoscopic or Robot-assisted Radical Trachelectomy with Type C1 Parametrectomy and Preservation of the Uterine Artery for Women With Early-stage Cervical Cancer: A Prospective Pilot Study |
110-GO2207:00~07:00 |
±èÈñÁ¤ ¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
Obesity is associated with higher long non-coding RNA SRA expression in endometrial cancer |
111-GO2307:00~07:00 |
±èÈñÁ¤ ¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
Upregulation of long non-coding RNA HOXA11 antisense promotes tumor metastasis via the Notch signaling pathway in cervical cancer |
112-GO2407:00~07:00 |
¹Ú½½±â ÀüÁÖ¿¹¼öº´¿ø »êºÎÀΰú |
°ñ¹Ý°°ú º¹° ³»·Î ÀüÆĵÇÁö ¾Ê°í Èĺ¹¸·ÀÓÆÄÀý¿¡ ÀüÀÌµÈ ³¼Ò¾Ï 1¿¹
|
113-GO2507:00~07:00 |
º¯Á¤¹Ì ÀÎÁ¦ÀÇ´ë ºÎ»ê¹éº´¿ø »êºÎÀΰú |
Efficacy of Human Papillomavirus Vaccines to Prevent the Recurrence
of Cervical Intraepithelial Neoplasia
|
114-GO2607:00~07:00 |
¼ºÁß¿± ÇѸ²ÀÇ´ë ¼º½Éº´¿ø »êºÎÀΰú |
Concurrent chemoradiation is better than systemic chemotherapy as a postoperative adjuvant therapy in advanced cervical cancer |
115-GO2707:00~07:00 |
¼ºÇýÀ± ÀÌÈ¿©ÀÚ´ëÇб³ ÀÇ°ú´ëÇÐ ¿©¼º¾ÏÁ¤º¹ Ư¼ºÈ ¿¬±¸¼¾ÅÍ |
Aberrant epigenetic regulation of gamma-aminobutyrate type A receptor pi subunit (GABRP)
associated with aggressive phenotype of ovarian cancer. |
116-GO2807:00~07:00 |
¼Û¹ÎÁ¾ °¡Å縯ÀÇ´ë ´ëÀü¼º¸ðº´¿ø »êºÎÀΰú |
Inhibitory effect of snake venom toxin on NF-¥êB activity prevents human cervical cancer cell growth via increase of death receptor 3 and 5 expression. |
117-GO2907:00~07:00 |
¼Û¹ÎÁ¾ °¡Å縯ÀÇ´ë ´ëÀü¼º¸ðº´¿ø »êºÎÀΰú |
Single port laparoscopic posterior pelvic exenteration |
118-GO3007:00~07:00 |
¼ÛÀº¼· ÀÎÇÏ´ëÇб³º´¿ø »êºÎÀΰú |
The clinical data of the patients with endometrioid endometrial cancer at an institution in Korea |
119-GO3107:00~07:00 |
¼ÛÁö¿µ °¡Å縯ÀÇ´ë ÀÇÁ¤ºÎ¼º¸ðº´¿ø »êºÎÀΰú |
Primary small cell neuroendocrine carcinoma of the vagina – A Case Report |
120-GO3207:00~07:00 |
½ÅÁ¤±Ô °æ»ó´ëÇб³º´¿ø »êºÎÀΰú |
Transcriptional activation of E6/E7 oncogenes by O-GlcNAcylated HCF-1 in HPV16/18-infected cervical cancers |
121-GO3307:00~07:00 |
À¯±ÔºÀ ´Ü±¹´ëÇб³º´¿ø »êºÎÀΰú |
Primary Ovarian Leiomyoma With Typical Meigs' Syndrome |
122-GO3407:00~07:00 |
À°Áø¼º °¼¹ÌÁî¸Þµðº´¿ø »êºÎÀΰú |
Comparison of survival outcomes in women with unsuspected uterine malignancy diagnosed after
laparotomic versus laparoscopic myomectomy: A national, population-based study |
123-GO3507:00~07:00 |
À±°¡¿µ ºÎ»ê´ëÇб³º´¿ø »êºÎÀΰú |
Disseminated polypoid endometriosis of the ovary mimicking advanced ovarian cancer: a case report and literature review |
124-GO3607:00~07:00 |
À±°¡¿µ ºÎ»ê´ëÇб³º´¿ø »êºÎÀΰú |
Mixed endometrial stromal and smooth muscle tumor of the uterus in a postmenopausal woman: a case report |
125-GO3707:00~07:00 |
À±Á¤¿ø ¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
The therapeutic and prognostic significance of systematic lymphadenectomy in patients
with advanced ovarian cancer at the time of interval debulking surgery after neoadjuvant
chemotherapy |
126-GO3807:00~07:00 |
ÀÌ°¡À» ÀüºÏ´ëÇб³º´¿ø »êºÎÀΰú |
Leiomyomatosis peritonealis disseminata: a case report |
127-GO3907:00~07:00 |
ÀÌ°æ³ë ÇѸ²ÀÇ´ë °³²¼º½Éº´¿ø »êºÎÀΰú |
Single-Lesion Measurement per Organ for Assessing Tumor
Response in Advanced Ovarian Cancer |
128-GO4007:00~07:00 |
ÀÌ´ë¿ì °¡Å縯ÀÇ´ë ºÎõ¼º¸ðº´¿ø »êºÎÀΰú |
SUPERIOR MESENTERIC ARTERY SYNDROME IN PATIENT WITH CERVICAL CANCER : A
CASE REPORT |
129-GO4107:00~07:00 |
À̸¶¸®¾Æ ¼¿ï´ëÇб³º´¿ø »êºÎÀΰú |
Postoperative radiotherapy versus chemoradiotherapy in stage III-IV endometrial cancer |
130-GO4207:00~07:00 |
ÀÌ¿µÀç ¿ï»êÀÇ´ë ¼¿ï¾Æ»êº´¿ø »êºÎÀΰú |
Feasibility of uterine preservation in the management of early- stage uterine adenosarcomas: a single institute experience |
131-GO4307:00~07:00 |
ÀÌÀ¯¿µ ¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø »êºÎÀΰú |
Dynamin inhibitors as a new anti-cancer agent in cervical carcinoma |
132-GO4407:00~07:00 |
ÀÌÀ±°æ °¡Å縯ÀÇ´ë ¼¿ï¼º¸ðº´¿ø »êºÎÀΰú |
Comparison of the HPV DNA chip test, the real time PCR HPV test and the Hybrid capture II test in Atypical Squamous Cells of Undetermined Significance population |
133-GO4507:00~07:00 |
ÀÌÀ翬 ¼¿ïƯº°½Ã º¸¶ó¸Åº´¿ø »êºÎÀΰú |
Analysis of clinicopathologic factors for subsequent surgery after initial conization with
positive resection margins |
134-GO4607:00~07:00 |
ÀÌÁ¤¿ø ¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø »êºÎÀΰú |
HER2 as a Novel Therapeutic Target for Cervical Cancer |
135-GO4707:00~07:00 |
ÀÌÁÖÇÐ °í·ÁÀÇ´ë ¾È¾Ïº´¿ø »êºÎÀΰú |
Peritoneal leiomyosarcoma arising from disseminated peritoneal leiomyomatosis after hysterectomy |
136-GO4807:00~07:00 |
ÀÌÅÂÀÓ ÇѸ²ÀÇ´ë µ¿Åº¼º½Éº´¿ø »êºÎÀΰú |
A malignant ovarian steroid cell tumor in a postmenopausal woman, managed with laparoscopic surgical staging: a case report |
137-GO4907:00~07:00 |
ÀÌÇöÁÖ ¿ï»êÀÇ´ë ¼¿ï¾Æ»êº´¿ø »êºÎÀΰú |
Comparison of MRI and 18F-FDG PET/CT in the Preoperative Evaluation of
Uterine Carcinosarcoma |
138-GO5007:00~07:00 |
ÀåÅÂ±Ô °è¸íÀÇ´ë µ¿»êÀÇ·á¿ø »êºÎÀΰú |
A retrospective comparison of Patient with locally advanced early stage cervical cancer(IB2~IIA) treated with concurrent chemoradiation versus radical hysterectomy with or without adjuvant therapy |
139-GO5107:00~07:00 |
ÀüÁöÇö ÀÌÈ¿©ÀÚ´ëÇб³ ÀÇ°ú´ëÇÐºÎ¼Ó ¸ñµ¿º´¿ø »êºÎÀΰú |
Robot-assisted laparoscopic adenomyomectomy of adenomyotic nodule implanted on uterine endometrium manifesting as endometrial cancer |
140-GO5207:00~07:00 |
Á¤µµ¿µ ¾È¾ç»ùº´¿ø |
The easy tying technique during single port laparoscopic surgery |
141-GO5307:00~07:00 |
Á¤¼öÈ£ ¼øõÇâÀÇ´ë ºÎõº´¿ø »êºÎÀΰú |
ÀӽŠÁß ¹ß°ßÇÑ Àڱ󻸷±âÁúÀ°Á¾ 1¿¹ |
142-GO5407:00~07:00 |
Á¤¾ð¼® ÇѸ²ÀÇ´ë ÇÑ°¼º½Éº´¿ø »êºÎÀΰú |
Technical and anatomical description of surgical boundary for systemic laparoscopic para-aortic lymphadenectomy up to the left renal vein level for women with gynecologic cancers |
143-GO5507:00~07:00 |
Á¤À¯¿¬ °¡Å縯ÀÇ´ë ¼ººó¼¾Æ®º´¿ø »êºÎÀΰú |
Effective therapeutic strategy for massive retroperitoneal hematoma after conization: arterial embolization and pig-tail catheter insertion |
144-GO5607:00~07:00 |
Á¶µ¿ÈÞ ÀüºÏ´ëÇб³º´¿ø »êºÎÀΰú |
³¼Ò¾Ï ¼¼Æ÷ÁÖ¿¡¼ AveULTRAÀÇ Ç×¾Ï È¿´É ¿¬±¸ |
145-GO5707:00~07:00 |
Á¶Çö¿õ °í·ÁÀÇ´ë ±¸·Îº´¿ø »êºÎÀΰú |
Correlation between the serum CA-125 levels and imaging findings after surgery in patients
with epithelial ovarian cancer |
146-GO5807:00~07:00 |
Á¶Çý¿¬ ÇѸ²ÀÇ´ë µ¿Åº¼º½Éº´¿ø »êºÎÀΰú |
Comparison of changes in serum anti-Mullerian hormone levels following laparoscopic
ovarian cystectomy and myomectomy |
147-GO5907:00~07:00 |
Áø¡ÈÖ ÀÌÈ¿©ÀÚ´ëÇб³ ÀÇ°ú´ëÇÐºÎ¼Ó ¸ñµ¿º´¿ø »êºÎÀΰú |
Association of plasma adiponectin and leptin in ovarian cancer development and progression |
148-GO6007:00~07:00 |
ÃÖ¹Îö Â÷ÀÇ°úÇдëÇб³ ºÐ´çÂ÷º´¿ø »êºÎÀΰú |
Finding founder mutations of BRCA1 and BRCA2 in Korean ovarian cancer patients |
149-GO6107:00~07:00 |
ÃÖÀοµ °æ»ó´ëÇб³º´¿ø »êºÎÀΰú |
Liposarcoma of the vulva
|
150-GO6207:00~07:00 |
ÃÖÁ¤ÀÎ °¡Å縯ÀÇ´ë ºÎõ¼º¸ðº´¿ø »êºÎÀΰú |
Does diabetes mellitus have an impact on the prognosis for patients with
cervical cancer? |
151-GO6307:00~07:00 |
ÃÖÇöÁø °æÈñÀÇ´ë °æÈñÀÇ·á¿ø »êºÎÀΰú |
Laparoscopic splenectomy of isolated splenic metastasis for recurrence of serous ovarian cancer ; a case report |
152-GO6407:00~07:00 |
ÇѽÃÀº ºÎ»ê´ëÇб³º´¿ø »êºÎÀΰú |
Large cell neuroendocrine carcinoma of the endometrium with cancer-associated retinopathy in a postmenopausal woman: a case report
|
153-GO6507:00~07:00 |
ÇѽÃÀº ºÎ»ê´ëÇб³º´¿ø »êºÎÀΰú |
Àڱ󻸷¾Ï ȯÀÚ¿¡¼ S100A4 ´Ü¹é¹ßÇöÀÇ ÀÓ»óº´¸®ÇÐÀû Á߿伺 |
154-GO6607:00~07:00 |
ȲÇýÁø °¡Å縯ÀÇ´ë ¼ººó¼¾Æ®º´¿ø »êºÎÀΰú |
A Case of Primary Malignant Mixed Mullerian Tumor of the Ovary |
ÀϹݿ¬Á¦ : ºÎÀÎÁ¾¾çÇÐ |
- ÀϽà : 2015³â 9¿ù 18ÀÏ (±Ý)
- Àå¼Ò : ¿¡¸Þ¶öµåȦ B[3F] |
GO1-GO4 (08:20~09:00) |
ÁÂÀå : À̳«¿ì(°í·ÁÀÇ´ë) |
GO108:20~08:30 |
¼Õ±Ý¼± ¿¬¼¼ÀÇ´ë °³²¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
Expanding Biospecimens from Korean Gynecologic Cancer Bank: Construction of Tissue Micro Arrays and Establishment of Immortalize Cell line. |
GO208:30~08:40 |
º¯½Â¿ø °¡Å縯ÀÇ´ë ÀÇÁ¤ºÎ¼º¸ðº´¿ø »êºÎÀΰú |
¾ÈÁ©¸®³ª Á¹¸®ÀÇ °áÁ¤ÀÌÈÄ BRCA mutation °Ë»ç ¹× ¿¹¹æÄ¡·á¿¡ ´ëÇÑ ÀνÄÁ¶»ç |
GO308:40~08:50 |
ÇÑ°æÈñ ¼¿ï´ëÇб³º´¿ø »êºÎÀΰú |
Residual ascites after neoadjuvant chemotherapy decreases treatment response and survival in patients with advanced-stage epithelial ovarian cancer |
GO408:50~09:00 |
±è¿µÅ ¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
The role of re-exploration in uterine sarcoma found incidentally after initial surgery for presumed benign disease |
GO5-GO8 (09:00~09:40) |
ÁÂÀå : ¹®Çý¼º(ÀÌÈÀÇ´ë) |
GO509:00~09:10 |
±è¿µÅ ¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
A scoring system to predict the risk of uterine sarcoma in patients with a uterine mass |
GO609:10~09:20 |
ÇãÀºÁø ¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø »êºÎÀΰú |
IGFBP5-derived peptide as a novel angiogenesis inhibitor for treatment of ovarian cancer |
GO709:20~09:30 |
¹ÚÈ¿°æ ¾ÆÁÖ´ëÇб³º´¿ø »êºÎÀΰú |
Transvaginal ultrasound-guided biopsy of adnexal masses as a useful diagnostic alternative replacing
cytology or laparoscopy in advanced ovarian cancer patients |
GO809:30~09:40 |
¹éÀ̼± ¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø »êºÎÀΰú |
Linalool-Incorporated Nanoparticles as a Novel Anticancer Agent for Epithelial Ovarian Carcinoma |
GO9-GO12 (09:40~10:20) |
ÁÂÀå : ÀÌÁ¾ÇÐ(°æ»óÀÇ´ë) |
GO909:40~09:50 |
±è¼±¾Æ
|
The prevalence of HPV infection in the semen among Korean men and the effect of HPV infection on sperm parameters |
GO1009:50~10:00 |
ÀÌ»óÈÆ °í·ÁÀÇ´ë ¾È¾Ïº´¿ø »êºÎÀΰú |
Validation of an algorithm in Korean Women Ages 21-24 years with either Atypical Squamous Cells of Undetermined Significance or Low-grade Squamous Intraepithelial Lesion |
GO1110:00~10:10 |
À±°Ç ¾ç»êºÎ»ê´ëÇб³º´¿ø »êºÎÀΰú |
Sphingosine kinase 1 is a reliable prognostic factor and a novel therapeutic target for uterine
cervical cancer |
GO1210:10~10:20 |
À¯¼ÒÀº
|
The risk factors and rate for progression of cervical intraepithelial lesions in HPV 16 or 18 infected women with ASCUS or LSIL: The Korean HPV cohort study. |
GO13-GO17 (10:50~11:40) |
ÁÂÀå : ±èÀçÈÆ(¿¬¼¼ÀÇ´ë) |
GO1310:50~11:00 |
±èÇöÁ¤ °Ç±¹´ëÇб³º´¿ø »êºÎÀΰú |
The impact of positive peritoneal cytology on prognosis in patients with cervical cancer: A meta-analysis |
GO1411:00~11:10 |
ÃÖÀ±Áø °¡Å縯ÀÇ´ë ¼¿ï¼º¸ðº´¿ø »êºÎÀΰú |
FROM CERVICAL INTRAEPITHELIAL NEOPLASIA TO CERVICAL SQUAMOUS CELL
CARCINOMA: AN INTEGRATIVE GENOMIC ANALYSIS |
GO1511:10~11:20 |
±èÅÂÈÆ ¿øÀÚ·ÂÀÇÇпø »êºÎÀΰú |
Outcome of salvage treatment for patients with recurrent cervical cancer; a single institutional
cohort study. |
GO1611:20~11:30 |
¼ÛÀçÀ± °í·ÁÀÇ´ë ¾È¾Ïº´¿ø »êºÎÀΰú |
Role of p16, p63, Ki67 in a two-tier system of low-grade and high-grade squamous intraepithelial lesion |
GO1711:30~11:40 |
¾ç¿ì°â ¿¬¼¼ÀÇ´ë °³²¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
Application of oncothermia using LabEHY-100 inhibits the growth of ovarian and cervical cancer cells. |
GO18-GO21 (11:40~12:30) |
ÁÂÀå : ¹ÚÁø¿Ï(´Ü±¹ÀÇ´ë) |
GO1811:40~11:50 |
µ¿¸Þ¾Æ¸® °Ç±¹´ëÇб³º´¿ø »êºÎÀΰú |
Impact of surgical staging on prognosis in patients with borderline ovarian tumors: a meta-analysis |
GO1911:50~12:00 |
À±Á¤¿ø ¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
Role of diagnostic laparoscopy in advanced epithelial ovarian cancer : An experience at a
single institution |
GO2012:00~12:10 |
À±°¡¿µ ºÎ»ê´ëÇб³º´¿ø »êºÎÀΰú |
Expression of interactive genes associated with apoptosis and their prognostic value for ovarian carcinoma |
GO2112:10~12:20 |
Á¤À±Áö ¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
Identifying association between obesity and ovarian cancer based on SRA-1 gene over-expression |
GO22-GO24 (13:40~14:10) |
ÁÂÀå : °í¼®ºÀ(´ë±¸°¡Å縯ÀÇ´ë) |
GO2213:40~13:50 |
À̹æÇö ¼¿ï´ëÇб³ ºÐ´çº´¿ø »êºÎÀΰú |
Efficacy of On-Q Pain Relief System for Postoperative Pain Management in Gynecologic
Oncology Patients: A pilot study |
GO2313:50~14:00 |
±è¹Ì¼± ¼¿ï´ëÇб³ ºÐ´çº´¿ø »êºÎÀΰú |
Identifying risk factors for CT-based diagnosed post-lymphadenectomy lower-extremity lymphedema in patients with gynecologic cancers |
GO2414:00~14:10 |
½Å¼¼ÀÎ °¡Å縯ÀÇ´ë ¼¿ï¼º¸ðº´¿ø »êºÎÀΰú |
Transcriptome analysis reveals that Müllerian inhibiting substance regulates signaling pathways that contribue to endometrial carcinogenesis |
ÀϹݿ¬Á¦ : ºÎÀÎÁ¾¾çÇÐ |
- ÀϽà : 2015³â 9¿ù 18ÀÏ (±Ý)
- Àå¼Ò : ´ÙÀ̾ƸóµåȦ[3F] |
GO25-GO28 (15:10~15:50) |
ÁÂÀå : À̼±°æ(°æÈñÀÇ´ë) |
GO2515:10~15:20 |
¹ÚÁöÀº Ä¥°î°æºÏ´ëÇб³º´¿ø »êºÎÀΰú |
Prognostic value of F-18 PET metabolic parameters of regional lymph node in locally advanced cervical cancer patients treated with concurrent chemoradiotherapy |
GO2615:20~15:30 |
³²¼¼Çö ¼º±Õ°üÀÇ´ë °ºÏ»ï¼ºº´¿ø »êºÎÀΰú |
Efficacy of TachoSil¢ç in preventing hemorrhage after loop electrosurgical excision procedure |
GO2715:30~15:40 |
Á¤À¯¿¬ °¡Å縯ÀÇ´ë ¼ººó¼¾Æ®º´¿ø »êºÎÀΰú |
Clipping during distal external iliac lymphadenectomy increases lower leg lymphedema in patients with carcinoma of the cervix |
GO2815:40~15:50 |
µµ¾Æ¿µ ¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø »êºÎÀΰú |
Prognostic factors affected survival outcome of recurrent cervical cancer patients with pulmonary metastases without other organs involvement |
GO29-GO31 (15:50~16:20) |
ÁÂÀå : Á¤ÀºÈ¯(ÃæºÏÀÇ´ë) |
GO2915:50~16:00 |
À̵ÎÇà ¼º±Õ°üÀÇ´ë °ºÏ»ï¼ºº´¿ø »êºÎÀΰú |
Effect of menstrual phase on the surgical treatment of ovarian cyst |
GO3016:00~16:10 |
À̼¼¿¬ Â÷ÀÇ°úÇдëÇб³ ºÐ´çÂ÷º´¿ø »êºÎÀΰú |
Oncologic and obstetric outcomes of conservative surgery for borderline ovarian tumor at reproductive age |
GO3116:10~16:20 |
Á¤ÀºÁÖ ¿ï»ê´ëÇб³º´¿ø »êºÎÀΰú |
Frequency of a non-rising increase of serum CA-125 levels during chemotherapy treatment in recurrent patients of advanced epithelial ovarian cancer (EOC) after reviously being treated optimally |